Why is this medication prescribed?

Empliciti (elotuzumab) is a prescription medication used in combination with other medications to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is specifically used in patients who have received one to three previous treatments for multiple myeloma.

It works by binding to a protein called SLAMF7, which is found on the surface of myeloma cells and natural killer cells of the immune system. By binding to SLAMF7, Empliciti helps the immune system to recognize and attack the myeloma cells more effectively.

Empliciti is typically prescribed in combination with other medications such as lenalidomide (Revlimid) and dexamethasone.

How should this medicine be used?

Empliciti (elotuzumab) is typically used in combination with other medications to treat multiple myeloma. The specific dosage and administration schedule of Empliciti will be determined by a healthcare professional based on factors such as the patient’s overall health, the stage of their cancer, and other medications they may be taking. Here are some general guidelines for using Empliciti:

• Administration: Empliciti is administered intravenously (IV) by a healthcare provider. It is typically given as a drip into a vein over a certain period of time. The infusion rate and duration will be determined by the healthcare provider.
• Combination therapy: Empliciti is usually used in combination with other medications such as lenalidomide (Revlimid) and dexamethasone. The specific combination and dosage will be determined by the healthcare provider based on the individual patient’s needs.
• Treatment schedule: The treatment schedule for Empliciti will vary depending on the specific treatment regimen prescribed by the healthcare provider. Treatment cycles may consist of several weeks, with regular intervals between cycles. Patients should follow the treatment schedule provided by their healthcare provider and attend all scheduled appointments.
• Monitoring: During treatment with Empliciti, patients will be monitored closely by their healthcare provider for any signs of side effects or complications. It’s important for patients to report any new or worsening symptoms to their healthcare provider promptly.
• Follow-up: After completing a course of treatment with Empliciti, patients will typically have follow-up appointments with their healthcare provider to monitor their response to treatment and assess for any signs of disease progression.

It’s important for patients to follow their healthcare provider’s instructions carefully and to attend all scheduled appointments for their Empliciti treatments. Additionally, patients should report any side effects or concerns to their healthcare provider promptly.

Other uses for this medicine

Empliciti (elotuzumab) is primarily used for the treatment of multiple myeloma in combination with other medications. However, it’s important to note that medications are typically prescribed for specific conditions and uses approved by regulatory agencies such as the FDA (Food and Drug Administration) in the United States. Off-label use of medications, meaning using them for conditions or purposes other than those approved by regulatory agencies, should only be done under the guidance and supervision of a healthcare professional.

What special precautions should I follow?

As for special precautions to follow when using Empliciti for its approved indication in treating multiple myeloma, here are some important considerations:

• Pre-treatment evaluation: Before starting Empliciti therapy, healthcare providers will conduct various assessments, including laboratory tests and evaluations of the patient’s overall health, to determine if the treatment is appropriate.
• Monitoring during treatment: Patients receiving Empliciti will be closely monitored by their healthcare provider for potential side effects and complications. This monitoring may include regular blood tests, physical examinations, and other assessments.
• Risk of infections: Empliciti treatment may increase the risk of infections. Patients should promptly report any signs or symptoms of infection, such as fever, chills, cough, or sore throat, to their healthcare provider.
• Infusion reactions: Like many intravenously administered medications, Empliciti can cause infusion reactions. Patients should be monitored closely during and after infusion for signs of infusion reactions, such as fever, chills, rash, itching, or difficulty breathing. Healthcare providers may administer medications to help manage these reactions.
• Blood clotting: Empliciti treatment may increase the risk of blood clotting (thrombosis). Patients should be monitored for signs of blood clots, such as swelling, pain, or redness in the arms or legs, and report any such symptoms to their healthcare provider.
• Pregnancy and breastfeeding: Empliciti may cause harm to a developing fetus, so it should not be used during pregnancy unless the potential benefits outweigh the risks. Women of childbearing age should use effective contraception during treatment and for a certain period afterward. It is not known whether Empliciti passes into breast milk, so breastfeeding should be avoided during treatment.
• Other medications: Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking, as some medications may interact with Empliciti.

It’s crucial for patients to discuss any questions or concerns about Empliciti treatment with their healthcare provider. They should also follow their healthcare provider’s instructions carefully and attend all scheduled appointments for monitoring and follow-up.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with Empliciti. However, it’s essential to maintain a balanced diet and stay well-hydrated during treatment. If you have any dietary concerns or restrictions, discuss them with your healthcare provider or a registered dietitian.

What should I do if I forget a dose?

Empliciti is typically administered by a healthcare provider in a clinical setting, so missing a dose is less likely. However, if you’re concerned about missing a scheduled appointment for Empliciti infusion, contact your healthcare provider as soon as possible to reschedule.

What side effects can this medication cause?

Empliciti (elotuzumab) can cause various side effects, some of which may be severe. It’s important for patients to be aware of potential side effects and to promptly report any new or worsening symptoms to their healthcare provider. Here are some common side effects associated with Empliciti:

• Infusion reactions: Infusion-related reactions, such as fever, chills, nausea, vomiting, rash, itching, and difficulty breathing, are common during or shortly after receiving Empliciti infusion. These reactions are usually mild to moderate but can sometimes be severe. Healthcare providers may administer medications to help manage these reactions.
• Infections: Empliciti may increase the risk of infections, including upper respiratory tract infections, pneumonia, urinary tract infections, and others. Patients should be vigilant for signs of infection, such as fever, chills, cough, or sore throat, and report any symptoms to their healthcare provider promptly.
• Fatigue: Fatigue or tiredness is a common side effect of Empliciti treatment. Patients may experience decreased energy levels, weakness, or difficulty performing daily activities.
• Diarrhea: Some patients may experience diarrhea as a side effect of Empliciti. It’s important to stay hydrated and notify your healthcare provider if diarrhea is severe or persistent.
• Constipation: Constipation is another gastrointestinal side effect that may occur with Empliciti treatment. Maintaining a healthy diet with plenty of fiber and fluids can help alleviate constipation.
• Peripheral neuropathy: Empliciti may cause peripheral neuropathy, which is characterized by numbness, tingling, or pain in the hands and feet. Patients should report any new or worsening symptoms of peripheral neuropathy to their healthcare provider.
• Thrombocytopenia: Empliciti may cause a decrease in the number of platelets in the blood, known as thrombocytopenia. This can increase the risk of bleeding. Patients should report any signs of bleeding, such as easy bruising or nosebleeds, to their healthcare provider.
• Respiratory tract infections: Respiratory tract infections, such as sinusitis, bronchitis, or pneumonia, may occur in some patients receiving Empliciti treatment.

These are not all the possible side effects of Empliciti. Patients should consult their healthcare provider for a complete list of side effects and any other concerns they may have about Empliciti treatment. It’s important to weigh the potential benefits of treatment against the risks of side effects and to discuss any questions or concerns with your healthcare provider.

What should I know about storage and disposal of this medication?

Storage and Disposal of Empliciti:

• Storage: Empliciti should be stored in the refrigerator at a temperature of 36°F to 46°F (2°C to 8°C). Do not freeze the medication. Keep Empliciti in its original carton to protect it from light. Do not shake the vial.
• Transportation: If necessary, Empliciti can be transported at room temperature (up to 77°F or 25°C) for a single period of up to 30 days. Once removed from refrigeration, the vial should not be returned to the refrigerator.
• Disposal: Unused or expired Empliciti should be disposed of properly according to local regulations and guidelines. Consult your healthcare provider or pharmacist for information on how to safely dispose of Empliciti.

In case of emergency/overdose

In the event of an overdose or if you experience severe adverse reactions after receiving Empliciti, seek immediate medical attention. Emergency services should be contacted immediately if you or someone else experiences symptoms such as difficulty breathing, severe allergic reactions, or other serious side effects.

What other information should I know?

• Monitoring: Your healthcare provider will closely monitor you during Empliciti treatment for any signs of side effects or complications. Be sure to attend all scheduled appointments and follow your healthcare provider’s instructions.
• Pregnancy and breastfeeding: Empliciti may harm a developing fetus, so it should not be used during pregnancy unless the potential benefits outweigh the risks. Women of childbearing age should use effective contraception during treatment and for a certain period afterward. It is not known whether Empliciti passes into breast milk, so breastfeeding should be avoided during treatment.
• Vaccinations: Inform your healthcare provider about all vaccinations you have received or plan to receive while undergoing treatment with Empliciti, as some vaccines may not be recommended or may be less effective during treatment.
• Blood tests: You may need to undergo regular blood tests during Empliciti treatment to monitor your blood cell counts and other parameters.
• Driving and operating machinery: Empliciti may cause fatigue or other side effects that could affect your ability to drive or operate machinery. Use caution until you know how Empliciti affects you.
• Follow-up care: After completing a course of treatment with Empliciti, you may need to undergo follow-up appointments and tests to monitor your response to treatment and assess for any signs of disease progression.

Always consult your healthcare provider or pharmacist for specific instructions and information regarding Empliciti treatment and any concerns you may have.